References
- Jones J, Lopez A, Wilson M. Congenital toxoplasmosis. Am Fam Physician 2003;67:2131–8
- Wallon M, Peyron F, Cornu C, et al. Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years. Clin Infect Dis 2013;56:1223–31
- Foulon W, Villena I, Stray-Pedersen B, et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children’s sequelae at age 1 year. Am J Obstet Gynecol 1999;180:410–15
- Kieffer F, Wallon M. Congenital toxoplasmosis. Handb Clin Neurol 2013;112:1099–101
- Ajzenberg D. Unresolved questions about the most successful known parasite. Expert Rev Anti Infect Ther 2011;9:169–71
- Edvinsson B, Lappalainen M, Evengård B. Real-time PCR targeting a 529-bp repeat element for diagnosis of toxoplasmosis. Clin Microbiol Infect 2006;12:131–6
- Paladini D, Volpe P. Ultrasound in fetal infection. In: Paladini D, Volpe P, eds. Ultrasound of congenital fetal anomalies. 2nd ed. Boca Raton: Taylor & Francis; 2014:437–52
- Pratlong F, Boulot P, Issert E, et al. Fetal diagnosis of toxoplasmosis in 190 women infected during pregnancy. Prenat Diagn 1994;14:191–8
- Hohlfeld P, MacAleese J, Capella-Pavlovski M, et al. Fetal toxoplasmosis: ultrasonographic signs. Ultrasound Obstet Gynecol 1991;1:241–4
- Thalib L, Gras L, Romand S, et al. Prediction of congenital toxoplasmosis by polymerase chain reaction analysis of amniotic fluid. BJOG 2005;112:567–74
- Wallon M, Franck J, Thulliez P, et al. Accuracy of real-time polymerase chain reaction for Toxoplasma gondii in amniotic fluid. Obstet Gynecol 2010;115:727–33
- Paquet C, Yudin MH, Society of Obstetricians and Gynaecologists of Canada. Toxoplasmosis in pregnancy: prevention, screening, and treatment. J Obstet Gynaecol Can JOGC J Obstétrique Gynécologie Can JOGC 2013;35:78–1
- Couvreur J, Desmonts G, Thulliez P. Prophylaxis of congenital toxoplasmosis. Effects of spiramycin on placental infection. J Antimicrob Chemother 1988;22:193–200
- Valentini P, Annunziata ML, Angelone DF, et al. Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy. Eur J Clin Microbiol Infect Dis off Publ Eur Soc Clin Microbiol 2009;28:297–300
- Hotop A, Hlobil H, Gross U. Efficacy of rapid treatment initiation following primary Toxoplasma gondii infection during pregnancy. Clin Infect Dis off Publ Infect Dis Soc Am 2012;54:1545–52
- Montoya JG, Remington JS. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis off Publ Infect Dis Soc Am 2008;47:554–66
- Fricker-Hidalgo H, Cimon B, Chemla C, et al. Toxoplasma seroconversion with negative or transient immunoglobulin M in pregnant women: myth or reality? A French multicenter retrospective study. J Clin Microbiol 2013;51:2103–11
- Gras L, Wallon M, Pollak A, et al. Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. Acta Paediatr 2005;94:1721–31
- Gilbert R, Gras L, European Multicentre Study on Congenital Toxoplasmosis. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG Int J Obstet Gynaecol 2003;110:112–20
- Valentini P, Buonsenso D, Barone G, et al. Spiramycin/cotrimoxazole versus pyrimethamine/sulfonamide and spiramycin alone for the treatment of toxoplasmosis in pregnancy. J Perinatol 2015;35:90–4